EUVIMEDEUVIMED entdecken
Crossref

Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice

Satoshi Hamada, Eriko Ogino, Hirotaka Yasuba

Respiratory Investigation · 2024

DOI: 10.1016/j.resinv.2024.06.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratory Investigation, 2024. Verfasst von Satoshi Hamada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606…. Hauptthemen laut MEDLINE: Omalizumab, Asthma, Anti-Asthmatic Agents, Severity of Illness Index. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The success rate of omalizumab discontinuation is 50-75.5%. However, such data are scarce in Japan. We retrospectively investigated the clinical progression following the cessation of long-term omalizumab treatment (>5 years) in severe allergic asthma patients who have achieved super-responder status, defined as being off any oral maintenance corticosteroids without experiencing exacerbations requiring systemic corticosteroids for >1 year. Six (28.6%) among 21 patients recommenced after a median period of 5.5 (4.3-12.5) months later due to exacerbated asthma control, resulting in improved asthma management for all patients. The rates of patients who successfully remained off omalizumab treatment for 1 and 2 years were 72.4% and 65.8%, respectively. Specific IgE levels after discontinuing omalizumab treatment significantly decreased compared to those at initiating this treatment in 10 patients who successfully remained off this treatment. Therefore, discontinuing omalizumab treatment may be considered for patients continuing treatment beyond 5 years and achieving super-responder status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabAsthmaAnti-Asthmatic AgentsSeverity of Illness IndexHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedImmunoglobulin ETime FactorsTreatment OutcomeDisease Progression

Stichwörter der Autor:innen

AsthmaDiscontinuationDisease-modifying anti-asthmatic drugsOmalizumabSpecific IgE

Substanzen

OmalizumabAnti-Asthmatic AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address: sh1124@kuhp.kyoto-u.ac.jp.
  • Ogino Clinic Kyoto, 717-2 Higashi Shiokoji-cho, Shimogyo-ku, Kyoto, 600-8216, Japan.
  • Department of Airway Medicine, Mitsubishi Kyoto Hospital, 1 Katsuragoshocho, Nishikyo-ku, Kyoto, 615-8087, Japan.

Zitieren

APA

Hamada, S., Ogino, E., & Yasuba, H. (2024). Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice. Respiratory Investigation. https://doi.org/10.1016/j.resinv.2024.06.005

Vancouver

Hamada S, Ogino E, Yasuba H. Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice. Respiratory Investigation. 2024. doi:10.1016/j.resinv.2024.06.005

BibTeX
@article{Hamada2024,
  author = {Hamada, Satoshi and Ogino, Eriko and Yasuba, Hirotaka},
  title = {Favorable clinical course after discontinuation of omalizumab treatment in patients with allergic severe asthma: A real-world clinical practice},
  journal = {Respiratory Investigation},
  year = {2024},
  doi = {10.1016/j.resinv.2024.06.005}
}
Kostenlos starten →